Clinical trial data support the NDA for TEV-'749, demonstrating that once-monthly olanzapine improves symptoms in patients with schizophrenia. The Food and Drug Administration (FDA) has accepted for ...
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE ...
PARSIPPANY, N.J. and TEL AVIV - Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Medincell (Euronext:MEDCL) announced today that the U.S. Food and Drug Administration has accepted their ...
INDIANAPOLIS The Food and Drug Administration has approved a long-acting injected form of a mental health drug by Eli Lilly & Co., the Indianapolis-based drug maker announced Monday. The FDA approved ...
March 23 (Reuters) - The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths. Elevated ...
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help ...
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results